Chimin Health Management
Market Cap
CN¥5.6b
Last Updated
2021/04/11 09:14 UTC
Data Sources
Company Financials
Executive Summary
Chimin Health Management Co., Ltd. develops, produces, and sells human drugs and medical devices in China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Solid track record with imperfect balance sheet.
Share Price & News
How has Chimin Health Management's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 603222 is more volatile than 90% of CN stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: 603222's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of CN stocks.
Market Performance
7 Day Return
4.3%
603222
-0.1%
CN Pharmaceuticals
-1.1%
CN Market
1 Year Return
-62.9%
603222
15.8%
CN Pharmaceuticals
28.4%
CN Market
Return vs Industry: 603222 underperformed the CN Pharmaceuticals industry which returned 14.4% over the past year.
Return vs Market: 603222 underperformed the CN Market which returned 27.4% over the past year.
Shareholder returns
| 603222 | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.3% | -0.1% | -1.1% |
| 30 Day | 4.8% | 3.9% | 1.0% |
| 90 Day | 55.5% | -5.4% | -5.8% |
| 1 Year | -62.8%-62.9% | 16.9%15.8% | 30.4%28.4% |
| 3 Year | n/a | 25.2%20.7% | 25.9%19.9% |
| 5 Year | 17.7%16.3% | 41.6%34.1% | 23.6%15.5% |
Long-Term Price Volatility Vs. Market
How volatile is Chimin Health Management's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Chimin Health Management undervalued compared to its fair value and its price relative to the market?
86.89x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 603222 (CN¥17.37) is trading above our estimate of fair value (CN¥0.55)
Significantly Below Fair Value: 603222 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 603222 is poor value based on its PE Ratio (86.9x) compared to the CN Pharmaceuticals industry average (30.9x).
PE vs Market: 603222 is poor value based on its PE Ratio (86.9x) compared to the CN market (34.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 603222's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 603222 is overvalued based on its PB Ratio (6.4x) compared to the CN Pharmaceuticals industry average (2.8x).
Future Growth
How is Chimin Health Management forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
24.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chimin Health Management has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Chimin Health Management performed over the past 5 years?
1.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 603222 has high quality earnings.
Growing Profit Margin: 603222's current net profit margins (7.9%) are higher than last year (5%).
Past Earnings Growth Analysis
Earnings Trend: 603222's earnings have grown by 1.2% per year over the past 5 years.
Accelerating Growth: 603222's earnings growth over the past year (70.6%) exceeds its 5-year average (1.2% per year).
Earnings vs Industry: 603222 earnings growth over the past year (70.6%) exceeded the Pharmaceuticals industry 10.9%.
Return on Equity
High ROE: 603222's Return on Equity (5.1%) is considered low.
Financial Health
How is Chimin Health Management's financial position?
Financial Position Analysis
Short Term Liabilities: 603222's short term assets (CN¥694.9M) do not cover its short term liabilities (CN¥863.5M).
Long Term Liabilities: 603222's short term assets (CN¥694.9M) exceed its long term liabilities (CN¥234.4M).
Debt to Equity History and Analysis
Debt Level: 603222's debt to equity ratio (79.4%) is considered high.
Reducing Debt: Insufficient data to determine if 603222's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 603222's debt is not well covered by operating cash flow (14.9%).
Interest Coverage: 603222's interest payments on its debt are well covered by EBIT (3.2x coverage).
Balance Sheet
Dividend
What is Chimin Health Management current dividend yield, its reliability and sustainability?
0.28%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 603222's dividend (0.28%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.42%).
High Dividend: 603222's dividend (0.28%) is low compared to the top 25% of dividend payers in the CN market (1.79%).
Stability and Growth of Payments
Stable Dividend: 603222 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 603222 has only been paying a dividend for 6 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (24%), 603222's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CN¥414k
CEO Compensation
CEO
Yunfei Tian (38 yo)
no data
Tenure
CN¥414,000
Compensation
Mr. Yunfei Tian serves as General Manager and Director of Chimin Health Management Co., Ltd. (formerly known as Zhejiang Chimin Pharmaceutical CO.,Ltd). Mr. Tian served as Manager of the Production Departm...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Chimin Health Management Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Chimin Health Management Co., Ltd.
- Ticker: 603222
- Exchange: SHSE
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥5.558b
- Shares outstanding: 320.00m
- Website: https://www.chimin.cn
Number of Employees
Location
- Chimin Health Management Co., Ltd.
- 888 North Road
- Huangyan
- Zhejiang Province
- 318020
- China
Listings
Biography
Chimin Health Management Co., Ltd. develops, produces, and sells human drugs and medical devices in China. The company offers non-PVC soft bag double tube double valves, single valves, and single-tube doub...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 09:14 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.